GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Ceftolozane / tazobactam (Zerbaxa)

Zerbaxa

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (2)

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (6)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

2 additional source qualifications - review before use
One-hour labeling versus institutional extended infusion

The RX label table uses a one-hour infusion. The UCSF protocol uses a three-hour infusion. Both also separate urinary/intra-abdominal infection from pneumonia/severe infection.

Before applying: Keep the selected source dose, indication, renal band, loading instruction and infusion duration together.

Pediatric renal guidance changed after the RX mirror

The older mirror lacks the age-specific renal regimens now supplied by the May 2026 label.

Before applying: Use the new pediatric card for ages two and older; verify indication, pediatric eGFR, weight caps and infusion time. Do not use adult Cockcroft-Gault bands as pediatric instructions.

Also check: One-hour labeling versus institutional extended infusion; Pediatric renal guidance changed after the RX mirror

Official source

ZERBAXA - May 2026 pediatric renal regimens

Product / population
Pediatric ZERBAXA age 2 to below 18 with renal impairment; May 2026 label, Table 4. Doses are total ceftolozane+tazobactam.
Renal measure
Validated pediatric eGFR, mL/min/1.73 m2; not adult Cockcroft-Gault.

Renal dosing, restrictions and evidence limits

Age 2 to below 18 years: use a validated pediatric eGFR equation (mL/min/1.73 m2). For cIAI/cUTI, total combination mg/kg every eight hours at eGFR 51 to below 90, 30-50 and 15-29 are respectively 30, 15 and 7.5; infuse over one hour. For HABP/VABP, corresponding doses are 75, 37.5 and 18.75 mg/kg every eight hours over two hours. Intermittent HD: cIAI/cUTI loads 15 mg/kg then 3 mg/kg every eight hours; pneumonia loads 45 mg/kg then 9 mg/kg every eight hours. Give post-HD doses as early as possible after dialysis. Above 50 kg for cIAI/cUTI or 40 kg for pneumonia, do not exceed the adult renal dose. Below eGFR 15 without HD, dosing is not established. Renal-impairment dosing is not recommended below age two. Reassess changing eGFR daily. cIAI also requires metronidazole. These 2026 regimens supersede the older mirror's broad pediatric renal evidence gap.

Source revision: May 2026 | Retrieved: 2026-09-07. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70ac1d90-eff3-4f0b-9f46-5846c571b32f

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 2 source difference / applicability notes

Official product label

ZERBAXA - adult indication-specific renal table

Adults; exact named U.S. product. Selected dose/renal summary, not the full prescribing information.

Renal method: Cockcroft-Gault CrCl, mL/min.
Retrieved: 2026-09-05

Official product label

ZERBAXA - May 2026 pediatric renal regimens

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Pediatric ZERBAXA age 2 to below 18 with renal impairment; May 2026 label, Table 4. Doses are total ceftolozane+tazobactam.

Renal method: Validated pediatric eGFR, mL/min/1.73 m2; not adult Cockcroft-Gault.
Retrieved: 2026-09-07

GlobalRPh RX List

GlobalRPh RX List - Zerbaxa

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Adult IV combined doses; cUTI/cIAI and HABP/VABP columns remain separate.

Renal method: CrCl by Cockcroft-Gault, mL/min.
Retrieved: 2026-09-07

GlobalRPh RX List

GlobalRPh RX List - ZERBAXA

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Adult IV ZERBAXA only in this older mirror; pediatric guidance is in the separate 2026 label card.

Renal method: Adult Cockcroft-Gault creatinine clearance, mL/min.
Retrieved: 2026-09-07

Professional guidance

UCSF - ZERBAXA: urinary versus severe infection

Adults; ceftolozane/tazobactam total combination doses IV; ID/stewardship restricted.

Renal method: CrCl in mL/min where specified; no equation inferred.
Retrieved: 2026-09-05

Professional guidance

Nebraska Medicine - ZERBAXA inpatient extended infusion

Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.

Renal method: CrCl in mL/min where specified; no equation inferred.
Retrieved: 2026-09-05

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Important v3.7 source / product limitation: Label-version change: the May 2026 DailyMed pediatric renal table is now local. Older pediatric evidence-gap statements remain historical; read the new age-specific source before selecting a regimen.
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

administration

One-hour labeling versus institutional extended infusion

The RX label table uses a one-hour infusion. The UCSF protocol uses a three-hour infusion. Both also separate urinary/intra-abdominal infection from pneumonia/severe infection.

How to use this: Keep the selected source dose, indication, renal band, loading instruction and infusion duration together.

Source difference identified; final patient-specific adjudication required.

label version update

Pediatric renal guidance changed after the RX mirror

The older mirror lacks the age-specific renal regimens now supplied by the May 2026 label.

How to use this: Use the new pediatric card for ages two and older; verify indication, pediatric eGFR, weight caps and infusion time. Do not use adult Cockcroft-Gault bands as pediatric instructions.

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Important source distinctions

U.S. labeling, UCSF and Nebraska distinguish indication and infusion duration. Nebraska uses a 4-hour inpatient infusion; the label uses 1 hour. Keep each renal table with its indication and infusion method.

Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70ac1d90-eff3-4f0b-9f46-5846c571b32f

Product and population scope

Adult Ceftolozane / tazobactam (Zerbaxa). Use only the product, route, indication and renal-replacement setting explicitly stated in the source protocol selected below. Sources are alternatives to compare, not ingredients of a blended regimen.

SCOPE-ceftolozane-tazobactam · Source section: Editorial scope; each clinical recommendation is separately attributed belowRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

ZERBAXA - adult indication-specific renal table

Open original reference

Open / share this exact local source

NIH/NLM DailyMed - U.S. product labeling · Adults; exact named U.S. product. Selected dose/renal summary, not the full prescribing information.

Renal method: Cockcroft-Gault CrCl, mL/min.
Source date: Label updated 2026-05-12; dosing changes May 2026.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

All adult doses are total combination amounts, IV every 8 hours over 1 hour. For cIAI/cUTI, baseline is 1.5 g; for HABP/VABP, 3 g. Add metronidazole for cIAI.

CrCl (mL/min)cIAI/cUTI doseHABP/VABP dose
30-50750 mg1.5 g
15-29375 mg750 mg
<15 without IHDNot establishedNot established
IHD750 mg loading, then 150 mg every 8 hours2.25 g loading, then 450 mg every 8 hours

On IHD days administer as soon as possible after completion. Monitor changing CrCl at least daily. The 51-to-<90 label band retains baseline doses. Pediatric renal and infusion schedules are separate and must not be inferred from these adult doses.

RDM30-068-ceftolozane-tazobactam-1 · Source locator: ZERBAXA - adult indication-specific renal table; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70ac1d90-eff3-4f0b-9f46-5846c571b32f
Retrieved
2026-09-05
DailyMed Set ID
70ac1d90-eff3-4f0b-9f46-5846c571b32f
Renal-function method
Cockcroft-Gault CrCl, mL/min.
Source date/version
Label updated 2026-05-12; dosing changes May 2026.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
a538b6193030702f3a44c9683248f19e1897e79c706307bd19c333b9f1636885
Official

ZERBAXA - May 2026 pediatric renal regimens

Open original reference

Open / share this exact local source

DailyMed / Merck Sharp & Dohme LLC · Pediatric ZERBAXA age 2 to below 18 with renal impairment; May 2026 label, Table 4. Doses are total ceftolozane+tazobactam.

Renal method: Validated pediatric eGFR, mL/min/1.73 m2; not adult Cockcroft-Gault.
Source date: May 2026
Retrieved: 2026-09-07

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

Age 2 to below 18 years: use a validated pediatric eGFR equation (mL/min/1.73 m2). For cIAI/cUTI, total combination mg/kg every eight hours at eGFR 51 to below 90, 30-50 and 15-29 are respectively 30, 15 and 7.5; infuse over one hour. For HABP/VABP, corresponding doses are 75, 37.5 and 18.75 mg/kg every eight hours over two hours. Intermittent HD: cIAI/cUTI loads 15 mg/kg then 3 mg/kg every eight hours; pneumonia loads 45 mg/kg then 9 mg/kg every eight hours. Give post-HD doses as early as possible after dialysis. Above 50 kg for cIAI/cUTI or 40 kg for pneumonia, do not exceed the adult renal dose. Below eGFR 15 without HD, dosing is not established. Renal-impairment dosing is not recommended below age two. Reassess changing eGFR daily. cIAI also requires metronidazole. These 2026 regimens supersede the older mirror's broad pediatric renal evidence gap.

RDM37-official-ceftolozane-tazobactam-3c655e39ee-C1 · Source locator: Sections 2.4 and 8.6, Table 4, including weight caps and dialysis footnotes.

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70ac1d90-eff3-4f0b-9f46-5846c571b32f
Retrieved
2026-09-07
Exact label title
ZERBAXA - May 2026 pediatric renal regimens
DailyMed Set ID
70ac1d90-eff3-4f0b-9f46-5846c571b32f
Labeler
Merck Sharp & Dohme LLC
Label revision
May 2026
Renal-function method
Validated pediatric eGFR, mL/min/1.73 m2; not adult Cockcroft-Gault.
Source date/version
May 2026
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
fe69cdec610a3608ade3ea4c85fa30769fa7de9fef865a7a571642016e3a2ed1
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - Zerbaxa

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Adult IV combined doses; cUTI/cIAI and HABP/VABP columns remain separate.

Renal method: CrCl by Cockcroft-Gault, mL/min.
Source date: Revision date not established in selected retrieval.
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Locally imported selected source sections; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

CrClcUTI/cIAIHABP/VABP
30-50750 mg every 8 hours1.5 g every 8 hours
15-29375 mg every 8 hours750 mg every 8 hours
HemodialysisLoad 750 mg, then 150 mg every 8 hoursLoad 2.25 g, then 450 mg every 8 hours

All doses are the combined ceftolozane/tazobactam quantity and are infused over one hour. On dialysis days give as soon as possible after dialysis. For changing renal function, assess CrCl at least daily and adjust accordingly. These are adult recommendations; no pediatric fallback is supplied. The three-hour infusion used in some institutional protocols is a separate source-specific approach.

RDM33-rxlist-ceftolozane-tazobactam-C1 · Source locator: Adult renal dosage table and footnotes.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/zerbaxa-drug/
Retrieved
2026-09-07
Renal-function method
CrCl by Cockcroft-Gault, mL/min.
Source date/version
Revision date not established in selected retrieval.
Hash meaning
SHA-256 of the local authored summary only; original HTML/PDF/SPL bytes are not bundled or hashed.
Local summary SHA-256
3531404aef088045a5b033becc93496d86712fa65afce63dc22245d5859c96f1
Rxlist

GlobalRPh RX List - ZERBAXA

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Adult IV ZERBAXA only in this older mirror; pediatric guidance is in the separate 2026 label card.

Renal method: Adult Cockcroft-Gault creatinine clearance, mL/min.
Source date: May 2022
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

Adult doses are total combination amounts, each infused over one hour every eight hours. For complicated intra-abdominal or urinary infection, the source uses 1.5 g above CrCl 50, 750 mg at 30-50, and 375 mg at 15-29 mL/min. For hospital-acquired/ventilator-associated pneumonia, corresponding doses are 3 g, 1.5 g and 750 mg. Hemodialysis: the abdominal/urinary regimen is a 750 mg loading dose then 150 mg every eight hours; pneumonia uses 2.25 g then 450 mg every eight hours. On dialysis days, administer after dialysis as early as possible. No nondialysis regimen below CrCl 15 is established. Recheck changing CrCl at least daily. Abdominal infection also requires metronidazole. This May 2022 mirror does not contain the pediatric renal regimens added to the separately stored May 2026 label.

RDM37-rxlist-ceftolozane-tazobactam-31f2723f84-C1 · Source locator: Adult dosing and renal Table 3; pediatric limitation; label revision.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/zerbaxa-drug/
Retrieved
2026-09-07
Renal-function method
Adult Cockcroft-Gault creatinine clearance, mL/min.
Source date/version
May 2022
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
9c5585dc7870d8fb1b9b6e28964c467e0db80e9a872997f522348a673963fe10
Separate professional-source layer

University and professional protocols

Professional

UCSF - ZERBAXA: urinary versus severe infection

Open original reference

Open / share this exact local source

UCSF Infectious Diseases Management Program · Adults; ceftolozane/tazobactam total combination doses IV; ID/stewardship restricted.

Renal method: CrCl in mL/min where specified; no equation inferred.
Source date: Revision date not stated in the reviewed page.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

Limits that apply to these rows

Loading and maintenance infusions all last 3 hours. This is the institutional prolonged-infusion strategy, not a silent replacement for labeling. No non-dialysis dose below the printed range is inferred.

Complicated UTI - combination IV amount over 3 hours
CrCl, mL/minSource-specific dose / instruction
>501.5 g every 8 hours
30-50750 mg every 8 hours
15-29375 mg every 8 hours
Pneumonia or severe infection - combination IV amount over 3 hours
CrCl, mL/minSource-specific dose / instruction
>503 g every 8 hours
30-501.5 g every 8 hours
15-29750 mg every 8 hours
Dialysis guidance - separate source-specific schedules
Ceftolozane/tazobactam dialysis
Dialysis setting / indicationSource-specific schedule
IHD - complicated UTI750 mg loading, then 150 mg every 8 hours
IHD - pneumonia/severe infection2.25 g loading, then 450 mg every 8 hours
Continuous HDNo regimen provided in the selected source
Read the retained text before reformatting

All listed infusions last 3 hours. For CrCl >50 / 30-50 / 15-29 mL/min:

  • Complicated UTI: total combination 1.5 g / 750 mg / 375 mg IV every 8 hours.
  • Pneumonia or severe infection: 3 g / 1.5 g / 750 mg IV every 8 hours.

IHD, complicated UTI: 750 mg loading, then 150 mg every 8 hours. IHD, pneumonia/severe infection: 2.25 g loading, then 450 mg every 8 hours. These loading and maintenance infusions also last 3 hours. The reviewed UCSF page provides no continuous-HD regimen. This institutional prolonged-infusion strategy is not silently substituted for the product label.

RDM30-007-ceftolozane-tazobactam-1 · Source locator: UCSF - ZERBAXA: urinary versus severe infection; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://idmp.ucsf.edu/content/ceftolozane-tazobactam-zerbaxa
Retrieved
2026-09-05
Renal-function method
CrCl in mL/min where specified; no equation inferred.
Source date/version
Revision date not stated in the reviewed page.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
6e09ee1c5cc263fbf3934f5125c0694b981817817e7bc7a14e373cdb5aee0ada
Professional

Nebraska Medicine - ZERBAXA inpatient extended infusion

Open original reference

Open / share this exact local source

Nebraska Medicine / UNMC · Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.

Renal method: CrCl in mL/min where specified; no equation inferred.
Source date: Retrieved PDF page 15; revision date not independently established
Retrieved: 2026-09-05

Source recheck unresolved. Prior follow-up retrieval/version warning retained; not resolved by v6.0. Read source-review status

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

Adults: cUTI/cIAI baseline 1.5 g IV every 8 hours; CrCl 30-50, 750 mg every 8 hours; 15-29, 375 mg every 8 hours; HD, 750 mg load then 150 mg every 8 hours.

HAP/VAP or septic shock: baseline 3 g every 8 hours; 30-50, 1.5 g every 8 hours; 15-29, 750 mg every 8 hours; HD, 2.25 g load then 450 mg every 8 hours. Inpatient infusions run over 4 hours, unlike the label's 1 hour. Only the adult rows are summarized.

RDM30-108-ceftolozane-tazobactam-1 · Source locator: Nebraska Medicine - ZERBAXA inpatient extended infusion; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://www.unmc.edu/intmed/_documents/id/asp/dose-nm-anti-infective-renal-dosing-guidelines.pdf
Retrieved
2026-09-05
Renal-function method
CrCl in mL/min where specified; no equation inferred.
Source date/version
Retrieved PDF page 15; revision date not independently established
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
d963026ae5b3236cd15d309c462f55fe40cab54b36b14ef5ccfdf87dfbca7262

Provenance and preservation

Additional summaries stored on this page: 2 official-label, 2 RX List, 2 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70ac1d90-eff3-4f0b-9f46-5846c571b32f
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
multisource addition
Local text SHA-256
51f009db2dbe65ff46213b4961f81359bc6d89aafa6dc811b065b110292ef15c
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report